Indivior PLC (INDV) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Indivior reported revenue of $1.24B, up 4.3% from $1.19B the year before. Net income was $210.0M (a 16.9% net margin), or $1.64 per diluted share. Gross margin was 80.2% and operating margin was 21.1%. Operating activities generated -$27.0M of cash, leaving -$93.0M of free cash flow. At fiscal year end, Indivior held $1.20B in total assets against $1.30B in total liabilities, including $195.0M of cash and equivalents.
Open the full interactive Indivior financials → Quarterly statements, key ratios, valuation history and price charts.
Indivior Key Stats
| Share Price | $35.42 |
|---|---|
| Market Cap | $4.39B |
| P/E Ratio | 21.6 |
| Revenue YoY Growth | +4.3% |
| 52-Week Range | $23.87 – $41.83 |
| Shares Outstanding | 119.0 million (basic, 2026 Q2) |
Indivior Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $1.19B | $1.24B |
| Cost of Goods Sold | $231.0M | $246.0M |
| Gross Profit | $957.0M | $994.0M |
| Operating Income | $32.0M | $262.0M |
| Pre-Tax Income | $14.0M | $239.0M |
| Income Tax | $11.0M | $29.0M |
| Net Income | $2.0M | $210.0M |
| Diluted EPS | $0.02 | $1.64 |
Indivior Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $314.0M | $357.0M | $317.0M | $343.0M |
| Net Income | $42.0M | $103.0M | $89.0M | $122.0M |
| Diluted EPS | $0.33 | $0.80 | $0.69 | $0.98 |
Indivior Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $319.0M | $195.0M |
| Current Assets | $839.0M | $652.0M |
| Total Assets | $1.32B | $1.20B |
| Current Liabilities | $939.0M | $914.0M |
| Total Long-Term Debt | $333.0M | $319.0M |
| Total Liabilities | $1.67B | $1.30B |
| Shareholders' Equity | -$348.0M | -$98.0M |
Indivior Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | $36.0M | -$27.0M |
| Cash From Investing | $69.0M | -$66.0M |
| Cash From Financing | -$102.0M | -$30.0M |
| Free Cash Flow | $7.0M | -$93.0M |
Figures from Indivior's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Indivior financials page for every line item.
Indivior Company Profile
| Ticker | INDV |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | North Chesterfield, Virginia |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001625297 |
Frequently Asked Questions
What was Indivior's revenue in fiscal 2025?
Indivior (INDV) reported revenue of $1.24B for fiscal 2025.
What was Indivior's net income in fiscal 2025?
Indivior reported net income of $210.0M for fiscal 2025.
What was Indivior's earnings per share (EPS) in fiscal 2025?
Indivior's diluted EPS was $1.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Indivior generate in fiscal 2025?
Indivior generated -$93.0M of free cash flow in fiscal 2025.
What was Indivior's revenue last quarter?
In its most recent reported quarter (2026 Q2), Indivior reported revenue of $343.0M.
How much debt does Indivior have?
Indivior reported $319.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Indivior are outstanding?
Indivior reported a weighted average of 119.0 million basic shares outstanding in 2026 Q2.
What is Indivior's market cap?
Based on its latest closing price, Indivior (INDV) has a market capitalization of about $4.39B.
When does Indivior's fiscal year end?
Indivior's fiscal year end, as registered with the SEC, is December 31.
Where is Indivior headquartered?
Indivior lists its business address in North Chesterfield, Virginia in its SEC filings.